HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

desethylamiodarone

metabolite of amiodarone; structure given in first source
Also Known As:
N-desethylamiodarone; deethylamiodarone; Methanone, (2-butyl-3-benzofuranyl)(4-(2-(ethylamino)ethoxy)-3,5-diiodophenyl)-
Networked: 35 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Komamura, Kazuo: 2 articles (12/2006 - 10/2005)
2. Ueno, Kazuyuki: 2 articles (12/2006 - 10/2005)
3. Kitakaze, Masafumi: 2 articles (12/2006 - 10/2005)
4. Fukumoto, Kyoko: 2 articles (12/2006 - 10/2005)
5. Kamakura, Shiro: 2 articles (12/2006 - 10/2005)
6. Kasanuki, H: 2 articles (11/2001 - 10/2001)
7. Shiga, T: 2 articles (11/2001 - 10/2001)
8. Papp, Julius Gy: 1 article (09/2015)
9. Leprán, István: 1 article (09/2015)
10. Varró, András: 1 article (09/2015)

Related Diseases

1. Myocardial Infarction
2. Cardiac Arrhythmias (Arrythmia)
10/01/2005 - "To evaluate the pharmacokinetic properties and an optimum dose schedule of amiodarone in long-term oral therapy, serum concentrations of amiodarone and its metabolite, desethylamiodarone, were monitored from 345 Japanese inpatients who received amiodarone therapy for a variety of cardiac arrhythmias. "
05/01/1987 - "Amiodarone and desethylamiodarone plasma concentrations and the effects of the drug on conduction intervals or right ventricular effective refractory periods were not related to suppression of arrhythmia induction by ventricular stimulation after 1 month of therapy. "
01/01/1985 - "At the time of reduction in the arrhythmia frequency, tissue levels of both amiodarone and desethylamiodarone in the border and infarct zone of the myocardium were approximately 50% as high as in the normal zone. "
01/01/1984 - "The concentrations of amiodarone (Cordarone) and desethylamiodarone in plasma after single oral and intravenous and long-term oral dosing were determined in seven normal subjects and 106 patients with various cardiac arrhythmias, respectively, using a high-performance liquid chromatographic method. "
06/01/1992 - "The decrease in TLCO was found to be significantly related to an increasing cumulated dose of amiodarone (p = 0.007), whereas the reduction in TLCO was found to be unrelated to sex, age, underlying heart disease, arrhythmia, daily dose of amiodarone, duration of treatment, plasma concentration of amiodarone and desethylamiodarone, and pretreatment pulmonary function abnormalities. "
3. Left Ventricular Dysfunction
4. Hyperlipoproteinemias
5. Heart Failure

Related Drugs and Biologics

1. Amiodarone (Amiodarona)
2. Metoprolol (Lopressor)
3. N 30
4. P-Glycoprotein
5. Warfarin (Coumadin)
6. Triiodothyronine (Liothyronine)
7. Sotalol (Sotalol Hydrochloride)
8. Flecainide (Tambocor)
9. Doxorubicin (Adriamycin)
10. Digoxin (Digitek)

Related Therapies and Procedures

1. Intravenous Infusions
2. Ligation
3. Cardiopulmonary Bypass (Heart-Lung Bypass)
4. General Anesthesia